Relmada Therapeutics, Inc.

RLMD · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$3,857$4,092$5,396$44,443
Short-Term Investments$41,052$92,232$142,927$167,466
Receivables$0$0$512$86
Inventory$0$0$0$0
Other Curr. Assets$886$1,185$4,035$11,302
Total Curr. Assets$45,796$97,509$152,870$223,298
Property Plant & Equip (Net)$0$0$0$0
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$22$43$35$28
Total NC Assets$22$43$35$28
Other Assets$0$0$0$0
Total Assets$45,818$97,552$152,905$223,326
Liabilities
Payables$4,131$3,506$5,262$11,193
Short-Term Debt$0$0$0$0
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$6,161$8,689$7,207$3,868
Total Curr. Liab.$10,291$12,195$12,469$15,061
LT Debt$0$0$0$0
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$4$0$0$0
Total NC Liab.$4$0$0$0
Other Liabilities$0$0$0$0
Cap. Leases$0$0$0$0
Total Liabilities$10,296$12,195$12,469$15,061
Equity
Pref Stock$0$0$0$0
Common Stock$30$30$30$28
Retained Earnings-$640,882-$560,903-$462,111-$305,067
AOCI$0$0$0$0
Other Equity$676,374$646,230$602,517$513,304
Total Equity$35,522$85,357$140,436$208,265
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$45,818$97,552$152,905$223,326
Net Debt-$3,857-$4,092-$5,396-$44,443